Which of the following represents a potential outcome of the FDA Modernization Act of 1997?

The FDA Modernization Act of 1997 aimed to streamline and enhance the drug approval process, which ultimately led to increased opportunities for research into new uses for existing medications. One of the key aspects of this legislation was the encouragement of innovation within the pharmaceutical industry, allowing for greater flexibility in how pharmaceutical companies could conduct research and submit data for new indications of already approved drugs. This act also facilitated the introduction of faster development and approval pathways for treatments, particularly for serious conditions. As a result, the act positively influenced the research landscape by promoting further investigation into potential new applications for drugs already on the market, thereby supporting the rapid advancement of medical therapies.

In contrast, other options present outcomes that do not align with the principal intentions and effects of the FDA Modernization Act. The act was designed to accelerate the approval process, not to slow it down or reduce standards, making the choice associated with increased research for new drug uses the most accurate reflection of its impact.